Wedbush initiates Catalyst Biosciences stock with Outperform rating

Published 14/07/2025, 12:44
Wedbush initiates Catalyst Biosciences stock with Outperform rating

Investing.com - Wedbush initiated coverage on Catalyst Biosciences (NASDAQ:CBIO) with an Outperform rating and a price target of $27.00 on Monday. According to InvestingPro data, the company, currently valued at $8.42 million, holds more cash than debt on its balance sheet, though the stock has declined 15.24% over the past week.

The research firm highlighted CBIO as an oncology-focused company developing a PD-1 x VEGF bispecific, CR-001, and two Top1i-ADC programs designed to treat solid tumors.

Wedbush noted that CR-001 recapitulates the critical features of leading PD-1 x VEGF bispecific ivonescimab, allowing CBIO to leverage ongoing clinical data updates and pursue de-risked opportunities as a fast-follower across solid tumor indications.

The firm expects CBIO’s additional Top1i-based ADC programs, CR-002 and CR-003, to enable synergistic combinations with CR-001 and drive differentiated activity with validated mechanisms.

Wedbush’s $27 price target represents significant upside potential for Catalyst Biosciences stock based on its current market valuation.

In other recent news, Crescent Biopharma has appointed Jan Pinkas, Ph.D., as its new chief scientific officer. Pinkas brings extensive experience in oncology drug development, notably in antibody-drug conjugates, which aligns with Crescent’s ongoing efforts in advancing its oncology pipeline. Meanwhile, GlycoMimetics has announced a 1-for-100 reverse stock split, set to take effect following its anticipated merger with Crescent Biopharma. This strategic move will significantly reduce GlycoMimetics’ outstanding common stock, although the total authorized common stock will remain unchanged.

Furthermore, GlycoMimetics has amended its merger agreement with Crescent Biopharma, as detailed in a recent 8-K filing with the SEC. The amendment includes adjustments to the exchange ratio for Crescent’s restricted stock units and clarifies voting mechanisms related to GlycoMimetics’ Series A Non-Voting Convertible Preferred Stock. The merger is structured as a stock-for-stock transaction, with Crescent shareholders expected to receive approximately 15.4192 shares of GlycoMimetics common stock for each Crescent share. Upon completion, Crescent security holders are anticipated to own about 97.4% of the merged entity, while GlycoMimetics shareholders will hold around 2.6%.

The SEC has yet to approve the securities involved in this transaction, and the merger remains subject to customary closing conditions. Investors are encouraged to review the Registration Statement on Form S-4 filed by GlycoMimetics for further details.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.